An electrophysiologic and ultrastructural study of the phenylmethanesulfonyl fluoride protection against a delayed organophosphorus neuropathy.
The delayed organophosphorus neuropathy caused by diisopropylfluorophosphate (DFP) can be prevented by pretreatment with phenylmethanesulfonyl fluoride (PMSF). A single injection of DFP (2 mg/kg) into a cat femoral artery produced a delayed neuropathy in the injected leg. Clinical neurotoxic signs in the DFP treated leg were most prominent at 21 to 28 days after DFP administration: a high-step gait with some tip-toe walking. During that time the capacity of the cat soleus alpha-motor nerve terminals to generate a stimulus-evoked repetitive discharge, known as SBR, was greatly attenuated. At that time, the ultrastructure of the motor nerve terminals demonstrated prominent alterations that correlated well with the motor nerve terminal SBR deficit. These alterations included the presence of extensive whorls in nerve terminals and axoplasms, the retraction and disruption of nerve terminals from the synaptic cleft, and a widening of secondary junctional folds. From the sampled population, the incidence of normal terminals in soleus muscles of the DFP-treated leg was only 2%. Cats which received PMSF (30 mg/kg ip) 24 hr before DFP administration did not develop any neurotoxic signs. Motor movements were normal. The SBR function of the soleus alpha-motor nerve terminals was not lost and its incidence approached normal values. Moreover, the ultrastructure was normal in 86% of examined neuromuscular junctions in the PMSF pretreated DFP cats. Thus, in this model, pretreatment with PMSF protected cats against the delayed neurotoxic effects of organophosphorus poisoning.
D000818:Animals; D002415:Cats; D004353:Drug Evaluation, Preclinical; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D005684:Gait; D007531:Isoflurophate / Q000506:poisoning*; D008297:Male; D009132:Muscles / Q000187:drug effects / Q000503:physiopathology; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D009469:Neuromuscular Junction / Q000187:drug effects / Q000503:physiopathology / Q000648:ultrastructure; D010664:Phenylmethylsulfonyl Fluoride / Q000627:therapeutic use*; D013450:Sulfones / Q000627:therapeutic use*; D013997:Time Factors
D013450:Sulfones; D007531:Isoflurophate; D010664:Phenylmethylsulfonyl Fluoride